REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 Rosetta Genomics, Ltd. (NASDQ: ROSG), the leadingdeveloper of microRNA-based molecular diagnostics, announced today it hassigned an exclusive distribution agreement with Teva PharmaceuticalIndustries Ltd. Under the terms of the agreement Teva will offer RosettaGenomics' miRview(TM) tests in Israel and Turkey. The terms of the deal werenot disclosed.
"This is yet another important step in Rosetta Genomics'commercialization efforts," noted Ronen Tamir, Chief CommercializationOfficer at Rosetta Genomics. "As Israel provided its citizens with healthinsurance under the National Health Law, it represents a very attractivemarket for us. Teva has gained unsurpassed experience in marketing andobtaining reimbursement for complex molecular tests in Israel, and we arevery excited to be partnering with them on these important tests. We are alsoexcited to have Teva distribute our tests in Turkey, a country withsignificant market potential."
Using microRNAs, a group of recently discovered non-coding genes found tobe highly sensitive biomarkers, Rosetta Genomics has developed proprietarytechnologies which can be the basis for a wide range of diagnostic tests.
The following tests will be distributed by Teva Pharmaceuticals:
- miRview(TM) mets - This test can accurately identify the primary tumorsite in patients presenting with metastatic cancer, as well in patients whosetumor has not been identified, and consequently been labeled Cancer ofUnknown Primary (CUP). As metastases need to be treated according to theirprimary origin, accurate identification of the metastases' primary origin canbe critical for determining appropriate treatment.Current diagnostic methodsto identify the origin of a metastasis include a wide range of costly, timeconsuming, and at times inefficient tests. miRview(TM) mets offers physicianswith a fast, accurate, and easy to interpret diagnosis of the predictedprimary origin.
- miRview(TM) squamous - Using a single microRNA, miRview(TM) squamousdifferentiates squamous from non-squamous, non-small cell lung cancer (NSCLC)patients. When administered targeted therapy, whether currently available orunder development, patients with squamous cell carcinoma of the lung havedemonstrated varying response patterns ranging from a high incidence ofsevere or fatal internal bleeding in the lungs to overall poor response totreatment. Current methods for differentiating squamous from non-squamousnon-small cell lung cancer are not standardized, are difficult to reproduce,and have low accuracy. miRview squamous produces a single score whichindicates whether a sample is squamous or non squamous NSCLC.
- miRview(TM) meso - The test leverages microRNA's high specificity asbiomarkers, to differentiate mesothelioma, a cancer connected to asbestosexposure, from other carcinomas in the lung. As mesothelioma patients requirespecific treatment regimens, accurately diagnosing mesothelioma is critical.Currently, there is no single diagnostic test that is entirely conclusive forthis differentiation. In addition, pathological diagnosis may suffer fromsignificant inter-observer variability, and in the absence of a singlespecific and reliable marker, mesothelioma can be difficult to identify fromother cancers. miRview(TM) meso is highly accurate test which may also assistphysicians to rule out mesothelioma in patients diagnosed with adenocarcinomain the lung who have been exposed to mesothelioma-related substances,primarily asbestos particles and heavy metals
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-basedmolecular diagnostics. Founded in 2000, the company's integrative researchplatform combining bioinformatics and state-of-the-art laboratory processeshas led to the discovery of hundreds of biologically validated novel humanmicroRNAs. Building on its strong IP position and proprietary platformtechnologies, Rosetta Genomics is working on the application of thesetechnologies in the development of a full range of microRNA-based diagnostictools. The company's first three microRNA-based tests, miRview(TM) squamous,miRview(TM) mets, and miRview(TM) meso, are commercially available throughits Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008winner of Wall Street Journal's Technology Innovation Awards in themedical/biotech category.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the role of microRNAs in human physiology and disease, thepotential of microRNAs in the diagnosis and treatment of disease, theexpected timing of submission for approval and launch of diagnostic testsusing our microRNA technology including miRview squamous and miRview metsconstitute forward-looking statements for the purposes of the safe harborprovisions under The Private Securities Litigation Reform Act of 1995. Actualresults may differ materially from those indicated by these forward-lookingstatements as a result of various important factors, including risks relatedto: Rosetta's approach to discover microRNA technology and to work on theapplication of this technology in the development of novel diagnostics andtherapeutic tools, which is unproven and may never lead to commerciallyaccepted products or services; Rosetta's ability to obtain, maintain andprotect its intellectual property; Rosetta's ability to enforce its patentsagainst infringers and to defend its patent portfolio against challenges fromthird parties; Rosetta's need and ability to obtain additional funding tosupport its business activities; Rosetta's dependence on third parties fordevelopment, manufacture, marketing, sales, and distribution of products;Rosetta's ability to successfully develop its candidate tools, products andservices,; Rosetta's ability to obtain regulatory clearances or approvalsthat may be required for its products and services; the ability to obtaincoverage and adequate payment from health insurers for the products andservices comprising Rosetta's technology; competition from others usingtechnology similar to Rosetta's and others developing products for similaruses; Rosetta's dependence on collaborators; and Rosetta's short operatinghistory; as well as those risks more fully discussed in the "Risk Factors"section of Rosetta's Annual Report on Form 20-F for the year ended December31, 2007 as filed with the Securities and Exchange Commission. In addition,any forward-looking statements represent Rosetta's views only as of the dateof this release and should not be relied upon as representing its views as ofany subsequent date. Rosetta does not assume any obligation to update anyforward-looking statements unless required by law.Contact: Media& Investors Ron Kamienchick T: 1-646- 509 1893 E: email@example.com
SOURCE Rosetta Genomics Ltd